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Abstract. Although overt hepatitis B virus (HBV) infec-
tion promotes the onset of hepatocellular carcinoma (HCC) 
in hepatitis C virus (HCV)-infected patients, the effect of 
occult HBV infection remains unclear. The aim of this study 
was to investigate the effect of occult HBV infection on the 
early-onset of HCC in HCV-infected patients. A total of 173 
HCC patients with HCV infection were enrolled and classified 
into 2 groups according to the median age of HCC onset: the 
early-onset group (n=91; 61.1±5.6 years) and the late-onset 
group (n=82; 73.8±3.7 years). Independent factors associated 
with the early-onset of HCC were assessed by multivariate 
analysis. In the overall analysis, independent risk factors for 
the early-onset of HCC were the white blood cell count and 
alanine aminotransferase level, but not the presence of HBV 
DNA. In a stratification analysis according to albumin levels 
of ≥3.5 g/dl, the presence of HBV DNA was a significant 
independent risk factor for the early-onset of HCC (OR 145.18, 
95% CI 1.38-15296.61, P=0.036), whereas the presence of 
antibodies against hepatitis B core antigen was not found to 
be a risk factor. The presence of HBV DNA was not a risk 
factor for the early-onset of HCC in the overall analysis. 
However, its presence was an independent factor for the 
early-onset of HCC in HCV-infected patients with an albumin 
level of ≥3.5 g/dl. Thus, occult HBV infection may accelerate 
hepatocarcino genesis in HCV-infected patients with relatively 
low carcinogenic potential.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common 
malignancies worldwide. It ranks third in men and fifth in 
women as the cause of death from malignancies in Japan (1). 
Chronic hepatitis C virus (HCV) infection is the major 
cause of HCC and accounts for ~60-70% of HCC cases in 
Japan (2). In addition to hepatic inflammation and subsequent 
fibrosis, various other factors including aging, obesity and 
diabetes mellitus are involved in the hepatocarcinogenesis in 
HCV-infected patients (3-5).
Co-infection of HCV with hepatitis B virus (HBV) 
is thought to synergistically increase the development of 
HCC (6). The status of HBV infection is evaluated by the pres-
ence of hepatitis B surface antigen (HBsAg), antibodies against 
hepatitis B core antigen (HBcAb), and HBV DNA. In some 
cases, HBV DNA can be detected in the serum or liver tissue 
of patients who are negative for HBsAg, a condition referred 
to as ‘occult HBV infection’ (7,8). In Japan, the prevalence of 
occult HBV infection in HCV-infected patients is reported 
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to be between 37.7% and 90% (9-11). Occult HBV infection 
is associated with a poor response to interferon therapy for 
chronic hepatitis C (12,13) and is also known to accelerate the 
progression of liver fibrosis, resulting in cirrhosis in patients 
with HCV infection (9,14,15). Several previous studies 
have examined the impact of occult HBV infection on the 
development of HCC in HCV-infected patients, but no clear 
conclusions have emerged (14,16,17). Moreover, the effects of 
occult HBV infection on the early-onset of HCC have not been 
investigated in HCV-infected patients.
Albumin is produced by hepatocytes, and the level of serum 
albumin is used to evaluate hepatic function (18). Albumin plays 
a significant role in maintaining colloid osmotic pressure and 
transports drugs and endogenous substances including bilirubin 
and unesterified free fatty acids (19). In addition, albumin exerts 
antioxidative properties (19), and hypoalbuminemia has been 
shown to be an independent risk factor for mortality among 
residents of a hyperendemic area of HCV infection in Japan (20). 
A serum albumin level of ≥3.5 g/dl is an independent predictor 
of survival in HCC patients (21,22) and in cirrhotic patients 
with a serum albumin levels of <3.5 g/dl, branched-chain amino 
acids increase serum albumin levels and subsequently suppress 
hepatocarcinogenesis (23,24). Thus, the serum albumin level is 
an important factor in hepatocarcinogenesis.
The aim of this study is to investigate the impact of occult 
HBV infection on the early-onset of HCC in HCV-infected 
patients. We also performed a stratification analysis according 
to the serum albumin level.
Subjects and methods
Subjects. We conducted a retrospective study to investigate 
the effect of the presence of HBV DNA on the early-onset 
of HCC in HCV-infected patients. Between 1995 and 2011, 
325 patients underwent hepatic resection at the Kurume 
University Hospital. The inclusion criteria were histologically 
proven HCC, a positive result for serum anti-HCV, and a 
negative result for serum HBsAg. Exclusion criteria were the 
presence of autoimmune hepatitis, primary biliary cirrhosis, 
and hemochromatosis, no test results for serum HBV DNA, 
and a histological diagnosis of combined hepatocellular and 
cholangiocellular carcinoma. Although 214 patients met the 
inclusion criteria, 41 patients had to be excluded because of 
one or more of these reasons. The remaining 173 HCC patients 
with HCV infection were therefore enrolled in this study and 
classified into 2 groups according to the median age of HCC 
onset: the early-onset group (n=91; 61.1±5.6 years) and the 
late-onset group (n=82; 73.8±3.7 years).
The study protocol was approved by the institutional 
review board, and informed consent for participation in the 
study was obtained from each subject. None of the subjects 
were institutionalized.
Data collection. Demographic data were collected at the time 
of hepatic resection including age, gender, and alcohol intake. 
Body mass index (BMI) was calculated as body weight in 
kilograms divided by the square of height in meters (kg/m2).
Venous blood samples were taken in the morning after a 
12-h overnight fast. The presence of serum anti-HCV, HBsAg, 
and HBcAb was tested using standard clinical methods 
(Department of Clinical Laboratory, Kurume University 
Hospital). Blood platelet count, white blood cell (WBC) count, 
prothrombin time %, plasma glucose levels; hemoglobin A1c 
(HbA1c) levels, and serum levels of aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), albumin, total 
bilirubin, insulin, α-fetoprotein (AFP), and des-γ-carboxy 
prothrombin (DCP) were also measured using standard clin-
ical methods. Insulin resistance was evaluated on the basis of 
fasting levels of plasma glucose and insulin, according to the 
homeostasis model assessment for insulin resistance (HOMA-
IR), as previously described (25).
The stage of hepatic fibrosis was assessed using the 
AST-to-platelet ratio index (APRI), which is calculated as 
the serum AST level (U/l)/upper limit of normal AST (U/l) 
x100/platelet count (x104/ml). Patients with APRI values 
of ≤1.5 were diagnosed as having chronic hepatitis, and 
patients with APRI values >1.5 were diagnosed as having 
liver cirrhosis, as previously described (26). The degree of 
liver cirrhosis was categorized according to the Child-Pugh 
classification (27). Diabetes mellitus was diagnosed on the 
basis of fasting blood glucose levels >126 mg/dl or HbA1c 
levels >6.5%, in accordance with the Diagnostic Criteria for 











Nucleotide positions are based on the sequence of hepatitis B virus subtype adr4 (GenBank accession no. X01587) (29).
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Diabetes Mellitus of the Japan Diabetes Society (28), or the 
use of antidiabetic agents.
Nucleic acid extraction from serum. Total nucleic acid was 
extracted from 300 µl of plasma using a commercially avail-
able kit (High Pure Viral Nucleic Acid kit; Roche Diagnostics, 
Tokyo, Japan) according to the manufacturer's instructions. 
The extracted nucleic acid was eluted in 25 µl of elution buffer.
PCR for HBV DNA. Serum HBV DNA was analyzed for 
the presence of HBs, HBc, and HBx (S, C and X) regions 
using TaqMan real-time PCR according to the manufac-
turer's instructions (TaqMan Fast Universal PCR Master 
mix; Applied Biosystems, Tokyo, Japan). The oligonucleotide 
primers and probes that were optimized for the HBV subtype 
adr4 (29) were specific for the S, X and C region sequences 
are listed in Table I. The full-length HBV DNA (GenBank 
accession no. X01587) (29) was used as an internal standard 
in the quantitative real-time detection PCR. We used 8 µl of 
nucleic acid-containing serum in our study for better sensi-
tivity. The limit of sensitivity of our TaqMan Real-time PCR 
methods was 4.5 copies/well, and the detection limit of our 
tests was 45 copies/ml (1.7 log copies/ml). A real-time PCR 
assay (COBAS TaqMan HBV Auto; Roche Diagnostics) was 
also performed to detect the core region of HBV DNA (limit 
of quantification, 1.8 log copies/ml). The presence of HBV 
DNA was defined as any positivity of S, X or C region.
Statistical analysis. Data are expressed as the absolute value 
or the mean ± SD. Differences between the early-onset and 
late-onset groups were analyzed using the Mann-Whitney U 
test. A logistic regression model with the Firth's correction 
30 was used for multivariate stepwise analysis to identify 
independent variables associated with the early-onset of HCC, 
as previously described (31,32). All P-values were 2-tailed, 
and a level of <0.05 was considered statistically significant. 
All statistical analyses were conducted using SAS version 9.2 
(SAS Institute, Cary, NC, USA) or R packages version 2.15.2 
(URL http://www.R-project.org/).
Results
Univariate analysis between the early-onset and late-onset 
groups. AFP levels, DCP levels, and maximal HCC size did not 
differ between the early-onset and late-onset groups (Table II). 
Furthermore, although BMI, WBC count, and serum insulin 
levels were significantly higher in the early-onset group than 
in the late-onset group, there were no significant differences 
Table II. Differences in the clinical characteristics between the early-onset and late-onset groups.
Variable Reference value Early-onset Late-onset P
Number of patients  91 82
Age (years)  61.1±5.6 73.8±3.7 <0.001
AFP (ng/ml) <8.7 1876±12163 769±3246 0.588
DCP (mAU/ml) <40 1083±4120 1071±3845 0.378
Maximal HCC size (mm) N/A 30.4±19.6 33.2±16.2 0.055
Gender (female/male) N/A 23/68 20/62 0.893
BMI (kg/m2) 18.5-22.0 23.6±3.6 22.4±3.2 0.045
Daily alcohol intake (none/0-60 g/>60 g) N/A 21/42/14 23/36/10 0.676
Platelet count (x104/mm3) 13-36 13.8±5.4 13.5±4.6 0.988
WBC count (/mm3) 4000-9000 5009±1526 4420±1210 0.012
AST (U/l) 13-33 56.2±29.5 52.8±27.2 0.412
ALT (U/l) 6-30 62.2±40.9 51.7±31.7 0.104
Albumin (g/dl) 4.0-5.0 3.87±0.45 3.85±0.38 0.520
Prothrombin time (%) 70-130 90.0±11.2 91.7±12.2 0.272
Total bilirubin (mg/dl) 0.3-1.2 0.84±0.35 0.79±0.29 0.346
Chronic hepatitis/Child-Pugh class A/Child-Pugh class B N/A 40/49/2 36/44/2 0.994
Complication of diabetes mellitus (yes/no) N/A 30/61 20/62 0.214
Fasting blood glucose (mg/dl) 80-109 119±39 107±31 0.060
Insulin (µU/ml) 5-20 13.1±10.4 9.8±8.0 0.014
HOMA-IR <2.5 3.05±2.47 2.11±1.03 0.622
HbA1c (%) 4.6-6.2 5.77±0.88 5.50±0.78 0.053
HBcAb positive/negative N/A 49/42 50/32 0.344
HBV DNA positive/negative N/A 6/85 3/79 0.385
Values are expressed as the mean ± SE. AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; HCC, hepatocellular carcinoma; BMI, body mass 
index; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment 
for insulin resistance; HbA1c, hemoglobin A1c; HBcAb, antibody for hepatitis B core antigen; HBV, hepatitis B virus; N/A, not applicable.
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in the daily alcohol intake, platelet count, prothrombin time, 
Child-Pugh classification, presence of diabetes mellitus as a 
comorbidity, fasting blood glucose level, HOMA-IR value, 
HbA1c levels, and the serum levels of AST, ALT, albumin, and 
total bilirubin (Table II). The presence of HBcAb and HBV 
DNA did not differ either between the early-onset and late-
onset groups (Table II).
Multivariate stepwise analysis for early-onset of HCC. 
Multivariate stepwise analysis showed that the serum ALT 
level and WBC count were independent risk factors for the 
early-onset of HCC (OR 1.10; 95% CI 1.00-1.21; P=0.045 and 
OR 1.35; 95% CI 1.06-1.73; P=0.014, respectively; Table III), 
but not the presence of HBcAb or HBV DNA.
Stratification analysis according to serum albumin level. 
Differences in the clinical characteristics between patients 
with the albumin level of ≥3.5 g/dl and <3.5 g/dl were summa-
rized in Table IV. There were no significant differences in 
AFP levels, DCP levels, and maximal HCC size between the 
albumin level of ≥3.5 g/dl and <3.5 g/dl groups (Table IV). In 
the albumin level of ≥3.5 g/dl group, a significant elevation 
was seen in platelet count, prothrombin time and the number 
of patients with chronic hepatitis and a significant depletion 
was seen in AST level than in the albumin level of <3.5 g/
dl group. However, other biochemical parameters and the 
Table III. Multivariate stepwise analysis for factors associated 
with the early-onset of hepatocellular carcinoma.
 Unit Odds ratio 95% CI P
HbA1c      1 1.37 0.91-2.07 0.136
BMI      1 1.08 0.98-1.19 0.133
ALT     10 1.10 1.00-1.21 0.045
DCP     20 0.99 0.98-1.00 0.091
WBC count 1000 1.35 1.06-1.73 0.014
All P-values were 2-tailed, and a level of <0.05 was considered statis-
tically significant. HbA1c, hemoglobin A1c; BMI, body mass index; 
ALT, alanine aminotransferase; DCP, des-γ-carboxy prothrombin; 
WBC, white blood cell.
Table IV. Differences in the clinical characteristics between patients with the albumin level of ≥3.5 g/dl and <3.5 g/dl.
 Albumin level of
 --------------------------------------------------------
Variable Reference value ≥3.5 g/dl <3.5 g/dl P
Number of patients  138 35
Age (years)  67.8±8.1 67.9±6.7 0.895
AFP (ng/ml) <8.7 786±3219 3262±18195 0.248
DCP (mAU/ml) <40 854±3269 1961±5977 0.306
Maximal HCC size (mm) N/A 30.6±15.9 36.8±23.8 0.171
Gender (female/male) N/A 35/103 8/27 0.759
BMI (kg/m2)  18.5-22.0 23.0±3.5 23.0±3.4 0.918
Daily alcohol intake (none/0-60 g/>60 g) N/A 21/58/38 3/20/6 0.172
Platelet count (x104/mm3) 13-36 14.3±4.9 11.3±4.8 0.001
WBC count (/mm3) 4000-9000 4798±1395 4291±1331 0.052
AST (U/l) 13-33 51.2±26.2 67.1±32.6 0.001
ALT (U/l) 6-30 54.9±37.4 63.4±32.7 0.057
Albumin (g/dl) 4.0-5.0 4.02±0.28 3.23±0.20 <0.001
Prothrombin time (%) 70-130 91.6±12.0 88.0±10.0 0.038
Total bilirubin (mg/dl) 0.3-1.2 0.82±0.34 0.80±0.28 0.822
Chronic hepatitis/Child-Pugh class A/Child-Pugh class B N/A 69/69/0 7/24/4 <0.001
Complication of diabetes mellitus (yes/no) N/A 38/100 12/23 0.431
Fasting blood glucose (mg/dl) 80-109 112±37 121±49 0.694
Insulin (µU/ml) 5-20 10.1±6.4 17.6±16.3 0.063
HOMA-IR <2.5 3.12±3.87 4.23±2.23 0.315
HbA1c (%) 4.6-6.2 5.61±0.79 5.68±1.04 0.905
HBcAb positive/negative N/A 75/63 24/11 0.129
HBV DNA positive/negative N/A 6/132 3/32 0.315
Values are expressed as the mean ± SE. AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; HCC, hepatocellular carcinoma; BMI, body mass 
index; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment 
for insulin resistance; HbA1c, hemoglobin A1c; HBcAb, antibody for hepatitis B core antigen; HBV, hepatitis B virus; N/A, not applicable.
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presence of HBcAb and HBV DNA did not differ between the 
albumin level of ≥3.5 g/dl and <3.5 g/dl groups (Table IV).
In patients with a serum albumin level of ≥3.5 g/dl, the 
WBC count and serum levels of albumin and DCP were iden-
tified as independent factors associated with the early-onset of 
HCC (OR 1.64; 95% CI 1.15-2.35; P=0.006, OR 1.17; 95% CI 
1.01-1.36; P=0.036, and OR 0.99; 95% CI 0.98-1.00; P=0.037, 
respectively; Table V). Although the presence of HBcAb was 
not found to be a significant risk factor for the early-onset of 
HCC, the presence of HBV DNA was identified as a significant 
independent risk factor associated with the early-onset of HCC 
(OR 145.18; 95% CI 1.38-15296.61; P=0.036; Table VI).
In patients with a serum albumin level of <3.5 g/dl, the 
serum AFP level was the only significant risk factor found 
to be associated with the early-onset of HCC (Table V). The 
presence of HBcAb and HBV DNA was not found to be a 
significant risk factor for the early-onset of HCC.
Discussion
In the overall analysis, the presence of HBV DNA in serum 
was not identified as a risk factor for the early-onset of HCC 
in HCV-infected patients. However, a stratification analysis 
according to a serum albumin level of ≥3.5 g/dl revealed that 
the presence of HBV DNA was an independent factor for the 
early-onset of HCC. These findings suggest that occult HBV 
infection may accelerate hepatocarcinogenesis in HCV-infected 
patients with a relatively low carcinogenic potential.
Although co-infection of HCV and HBV is thought to 
synergistically increase the risk of HCC (6), the overall 
analysis in this study showed that occult HBV infection was 
not significantly associated with the early-onset of HCC in 
HCV-infected patients. Similarly, several studies conducted 
in Asia have also failed to show any significant effect of 
occult HBV infection in these patients (33-35). Recently, 
Lok et al (36) performed a nested case-control study using 
a large number of patients enrolled in the HALT-C cohort 
and reported no significant difference in the prevalence of 
occult HBV infection between HCC and non-HCC patients 
with HCV infection. Taken together, these results suggest that 
occult HBV infection may not be an intensive promoter of 
HCC development in the presence of a potent carcinogenic 
factor such as HCV infection.
In contrast with these previous studies and with our own 
findings for all patients, a stratification analysis according to a 
serum albumin level of ≥3.5 g/dl showed that occult HBV infec-
tion was an independent risk factor for the early-onset of HCC. 
In patients with occult HBV infection, it is unclear whether a 
presence of HBV DNA is due to full-length HBV DNA repli-
cated from covalently closed circular DNA in hepatocytes or 
fragmented HBV DNA integrated into the hepatocyte genome. 
However, the HBx gene is frequently integrated into cellular 
genes in HCC (37). The HBx protein upregulates the expres-
sion of proto-oncogenes including c-jun, c-fos and c-myc, all of 
which can promote hepatocarcinogenesis (38,39). In addition, 
albumin plays a crucial role in the development of various 
diseases, as it is a major antioxidant (19). In cirrhotic patients 
with a serum albumin level of <3.5 g/dl, branched-chain amino 
acids increase serum albumin levels, and this subsequently 
suppresses hepatocarcinogenesis (23,24). In this study, we 
found a significant association between occult HBV infection 
and the early-onset of HCC in patients with a serum albumin 
level of ≥3.5 g/dl, but not in patients with a serum albumin level 
of <3.5 g/dl. Taken together, these findings suggest that HBV 
DNA may promote hepatocarcinogenesis in HCV-infected 
patients with relatively low carcinogenic potential.
Table V. Multivariate stepwise analysis for factors associated with the early-onset of hepatocellular carcinoma in patients with a 
serum albumin level of ≥3.5 g/dl.
 Unit Odds ratio 95% CI P
HBcAb  Positive 0.59 0.27-1.26 0.169
HBV DNA  Positive 145.18 1.38-15296.61 0.036
Prothrombin time 10 0.76 0.54-1.08 0.109
ALT 10 1.08 0.97-1.21 0.145
Albumin 0.1 1.17 1.01-1.36 0.036
DCP 20 0.99 0.98-1.00 0.037
Platelet count 1 0.92 0.84-1.02 0.107
WBC count 1000 1.64 1.15-2.35 0.006
All P-values were 2-tailed, and a level of <0.05 was considered statistically significant. HBcAb, antibody for hepatitis B core antigen; HBV, 
hepatitis B virus; ALT, alanine aminotransferase; DCP, des-γ-carboxy prothrombin; WBC, white blood cell.
Table VI. Multivariate stepwise analysis for factors associated 
with the early-onset of hepatocellular carcinoma in patients 
with a serum albumin level of <3.5 g/dl.
 Unit Odds ratio 95% CI P
HbA1c   1 1.83 0.75-4.47 0.183
HBV DNA Positive 0.00 0.00-2.96 0.093
AFP 20 1.39 1.01-1.93 0.045
All P-values were 2-tailed, and a level of <0.05 was considered statis-
tically significant. HbA1c, hemoglobin A1c; HBV, hepatitis B virus; 
AFP, α-fetoprotein.
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Although we designed this study to investigate the effect of 
HBV DNA on the early-onset of HCC in HCV-infected patients, 
we found instead that an elevated WBC count is an indepen-
dent risk factor for the early-onset of HCC in HCV-infected 
patients. An elevated WBC count may reflect the conse-
quences or underlying pathogenesis of the early-onset of HCC. 
One possible explanation is aging, because the WBC count 
declines in old age (40). Alternatively, an elevated WBC count 
still within the reference range is known to be associated with 
the development of various malignancies including gastric, 
colorectal, endometrial and lung cancers (41,42). The WBC 
count is a well-validated biomarker of inflammation. Chronic 
inflammation is a possible risk factor for hepatocarcinogenesis 
as it leads to the activation of receptors for chemokine and 
advanced glycation-end products (43,44). Another inflamma-
tion marker, C-reactive protein, is reported to be a diagnostic 
and prognostic marker of HCC (45,46). Taken together, these 
findings suggest that inflammation may promote the early-
onset of HCC in HCV-infected patients.
A limitation of this study is that there were only a small 
number of HBV DNA-positive patients. Previous studies 
regarding occult HBV infection had a similar limita-
tion (33,47,48). Since occult HBV infection is not frequently 
seen in HCV-infected patients with HCC, a multicenter study 
is needed to confirm our findings.
In conclusion, the presence of HBV DNA in serum was 
not a risk factor for the early-onset of HCC in HCV-infected 
patients. However, a stratification analysis based on a serum 
albumin level of ≥3.5 g/dl revealed that presence of HBV DNA 
in serum was an independent risk factor for the early-onset of 
HCC. These findings suggest that occult HBV infection may 
accelerate hepatocarcinogenesis in HCV-infected patients 
with relatively low carcinogenic potential.
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